Fritz Lang

781 total citations
16 papers, 640 citations indexed

About

Fritz Lang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Fritz Lang has authored 16 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Fritz Lang's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Fritz Lang is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Fritz Lang collaborates with scholars based in Austria, Germany and India. Fritz Lang's co-authors include Gabriela Kornek, Werner Scheithauer, D. Depisch, Markus Raderer, Bruno Schneeweiß, B. Schüll, E. Kovats, Katharina Schmid, A. Lenauer and K. Haider and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Fritz Lang

16 papers receiving 627 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fritz Lang Austria 12 534 240 187 115 88 16 640
Jean‐Marie Tigaud France 13 477 0.9× 387 1.6× 191 1.0× 77 0.7× 110 1.3× 20 736
S. Rigatos Greece 13 396 0.7× 200 0.8× 74 0.4× 99 0.9× 34 0.4× 31 497
A. Arriví Spain 10 380 0.7× 121 0.5× 189 1.0× 124 1.1× 33 0.4× 18 546
Ioannis Xanthakis Greece 12 347 0.6× 161 0.7× 130 0.7× 93 0.8× 57 0.6× 30 519
Lambros Vamvakas Greece 17 597 1.1× 370 1.5× 71 0.4× 164 1.4× 49 0.6× 44 759
Emiddio Barletta Italy 12 395 0.7× 336 1.4× 66 0.4× 82 0.7× 38 0.4× 28 584
N. Androulakis Greece 14 638 1.2× 326 1.4× 122 0.7× 65 0.6× 191 2.2× 29 721
Yvonne Lassere United States 14 761 1.4× 320 1.3× 205 1.1× 58 0.5× 69 0.8× 20 887
Beate Haugk United Kingdom 15 326 0.6× 139 0.6× 211 1.1× 82 0.7× 72 0.8× 40 590
J.-L. Canon Belgium 11 486 0.9× 197 0.8× 106 0.6× 44 0.4× 177 2.0× 22 685

Countries citing papers authored by Fritz Lang

Since Specialization
Citations

This map shows the geographic impact of Fritz Lang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fritz Lang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fritz Lang more than expected).

Fields of papers citing papers by Fritz Lang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fritz Lang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fritz Lang. The network helps show where Fritz Lang may publish in the future.

Co-authorship network of co-authors of Fritz Lang

This figure shows the co-authorship network connecting the top 25 collaborators of Fritz Lang. A scholar is included among the top collaborators of Fritz Lang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fritz Lang. Fritz Lang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Vormittag, Laurenz, Andreas Gleiß, Werner Scheithauer, et al.. (2009). Limited Value of CA 19-9 in Predicting Early Treatment Failure in Patients with Advanced Pancreatic Cancer. Oncology. 77(2). 140–146. 8 indexed citations
2.
Vormittag, Laurenz, Gabriela Kornek, A. Lenauer, et al.. (2007). UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer – a retrospective analysis. Anti-Cancer Drugs. 18(6). 709–712. 14 indexed citations
3.
Ulrich-Pur, H., Gabriela Kornek, K. Haider, et al.. (2006). Phase II trial of pegylated liposomal doxorubicin (Caelyx™) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer. Acta Oncologica. 46(2). 208–213. 10 indexed citations
4.
Schuell, B., Thomas Gruenberger, Gabriela Kornek, et al.. (2005). Side effects during chemotherapy predict tumour response in advanced colorectal cancer. British Journal of Cancer. 93(7). 744–748. 47 indexed citations
5.
Kornek, Gabriela, B. Schuell, Friedrich Laengle, et al.. (2004). Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology. 15(3). 478–483. 110 indexed citations
6.
Haider, K., Gabriela Kornek, W. Kwasny, et al.. (2004). Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC. Journal of Clinical Oncology. 22(14_suppl). 696–696. 4 indexed citations
7.
Ulrich-Pur, H., Markus Raderer, Gabriela Kornek, et al.. (2003). Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. British Journal of Cancer. 88(8). 1180–1184. 98 indexed citations
8.
9.
Scheithauer, Werner, Gabriela Kornek, Markus Raderer, et al.. (2003). Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 21(7). 1307–1312. 141 indexed citations
10.
Scheithauer, Werner, Gabriela Kornek, Stefan Brugger, et al.. (2002). Randomized Phase II Study of Irinotecan Plus Mitomycin C vs. Oxaliplatin Plus Mitomycin C in Patients with Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer. Cancer Investigation. 20(1). 60–68. 24 indexed citations
11.
Kornek, Gabriela, K. Haider, W. Kwasny, et al.. (2002). Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.. PubMed. 8(5). 1051–6. 40 indexed citations
12.
Kornek, Gabriela, Markus Raderer, B. Schüll, et al.. (2002). Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. British Journal of Cancer. 86(12). 1858–1863. 32 indexed citations
13.
Scheithauer, Werner, Gabriela Kornek, Markus Raderer, et al.. (2002). Randomized Multicenter Phase II Trial of Oxaliplatin Plus Irinotecan Versus Raltitrexed as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 20(1). 165–172. 21 indexed citations
14.
Kornek, Gabriela, H. Ulrich-Pur, K. Haider, et al.. (2001). Treatment of Advanced Breast Cancer with Vinorelbine and Docetaxel With or Without Human Granulocyte Colony-Stimulating Factor. Journal of Clinical Oncology. 19(3). 621–627. 36 indexed citations
15.
Scheithauer, Werner, Gabriela Kornek, Markus Raderer, et al.. (1999). Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. British Journal of Cancer. 80(11). 1797–1802. 39 indexed citations
16.
Ulrich-Pur, H., S. Brugger, Wolfgang Fiebiger, et al.. (1999). Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC). European Journal of Cancer. 35. S72–S73. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Marie Tigaud Breakdown of academic impact, for papers by S. Rigatos Breakdown of academic impact, for papers by A. Arriví Breakdown of academic impact, for papers by Ioannis Xanthakis Breakdown of academic impact, for papers by Lambros Vamvakas Breakdown of academic impact, for papers by Emiddio Barletta Breakdown of academic impact, for papers by N. Androulakis Breakdown of academic impact, for papers by Yvonne Lassere Breakdown of academic impact, for papers by Beate Haugk Breakdown of academic impact, for papers by J.-L. Canon
Rankless by CCL
2026